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ABSTRACT 
In Burkitt lymphoma/leukemia (BL), achievement of complete remission (CR) with first-
line chemotherapy remains a challenging issue, as most patients who respond initially 
remain disease-free whereas those refractory have few options to be rescued with 
salvage therapies. The mechanisms underlying BL chemoresistance and how it can 
be circumvented are not completely known. Our previous integrative genomic analysis 
identified genetic and epigenetic inactivation of pro-apoptotic BIM gene in B-cell 
lymphomas. Here we show that BIM epigenetic silencing by concurrent promoter 
hypermethylation and deacetylation occurred frequently in primary BL samples and 
BL-derived cell lines. Remarkably, patients with hypermethylated BIM presented lower 
complete remission rate (24% vs. 79%;p=0.002) and shorter overall survival (p=0.007) 
than those with BIM-expressing lymphomas, indicating that BIM transcriptional 
repression may have mediated tumor chemoresistance. Accordingly, by combining in 
vitro and in vivo studies of human BL-xenografts grown in immunodeficient RAG2-/-
IL2γc-/- mice and of mature B-cell lymphomas generated in Eμ-MYC and Eμ-MYC-
BIM+/- transgenes, we demonstrate that chemoresistance is dictated by BIM gene 
dosage and that is reversible upon BIM reactivation by genetic manipulation or with 
histone-deacetylase inhibitors such as Vorinostat. We suggest that Vorinostat 
combined with high-dose chemotherapy may overcome chemoresistance, achieve 
durable remission and improve survival of patients with BL.  
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INTRODUCTION 
 
Burkitt lymphoma/leukemia (BL) is a clinically aggressive B-cell malignancy 
accounting for between 85 and 90% of childhood and less than 5% of adult B-cell 
lymphomas in Europe and the United States. Three clinical variants are recognized by 
the WHO classification: sporadic, endemic or related to Epstein-Barr virus (EBV) 
infection,  and human immunodeficiency virus (HIV)-associated.1 Besides the typical 
cytologic and immunophenotypic findings, the characteristic hallmark of BL is the 
presence of chromosomal translocations deregulating MYC oncogene.2 Clinically, the 
presence of older age, advanced tumor stage with bone marrow and leukemic 
disease, increased serum LDH and immunodeficiency have been correlated with poor 
outcome. However, there is not a clinical or biological marker able to predict 
responses to therapy.3-6 
 
Current treatment for patients with BL includes multi-agent, dose-intensive 
chemotherapy regimens with central nervous system prophylaxis, which can achieve 
complete remission (CR) in around 90-95% of children and 60-70% of adults. The 
most critical issue in BL remains to achieve an initial CR, because those patients who 
respond to first-line chemotherapy have a high probability of remaining free of 
disease.3,6,7 Conversely, patients who present primary chemoresistance or early 
relapse usually die early because of progressive disease or of therapeutic 
complications while attempting to achieve remission.3,8 Salvage chemotherapy has 
been effective in up to one-third of children with refractory or relapsed BL, but no 
similar successful treatment has been reported for adults.9  
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Despite this clinical dilemma, the molecular basis of BL chemoresistance and, more 
importantly, how it can be circumvented, have not been elucidated.10-13 We have 
previously reported that the gene encoding the pro-apoptotic BH3-only family member 
protein BIM is frequently inactivated by genetic and epigenetic abnormalities that vary 
substantially among the different B-cell lymphoma subgroups.14 In some solid tumors 
and myeloid leukemias, BIM is commonly inactivated by post-transcriptional 
modifications that target it for degradation in the proteasome, leading to therapeutic 
resistance.15-19 In addition, BIM is a suppressor of MYC-induced B-cell leukemias in 
mice.20,21 However, whether BIM mediates chemotherapeutic resistance in mature B-
cell lymphomas has not been addressed. In this report, we show that resistance to 
chemotherapy in patients with BL is dictated by the epigenetic silencing of BIM, and 
that this resistance can be reversed by reactivating BIM expression with histone 
deacetylase inhibitors (HDACis) such as the suberoylanilide hydroxiamic acid (SAHA, 
Vorinostat). Consequently, the combination of Vorinostat and high-dose chemotherapy 
may be of clinical benefit in patients with BL to prevent refractory disease. 
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MATERIALS AND METHODS 
 
Burkitt lymphoma/leukemia primary biopsies and cell lines  
Thirty-nine lymph node biopsies (n=12) or bone marrow aspirates (n=27) from HIV-
negative Spanish patients diagnosed of Burkitt lymphoma/leukemia according to the 
World Health Organization (WHO) criteria and obtained before initiation of therapy 
were included in the study. Cases with atypical BL or with Burkitt-like lymphoma were 
excluded (Supplementary-Table 1). All evaluated lymphomas presented chromosomal 
translocations involving MYC gene: t(8;14)(q24;q32) (n=30), t(2;8)(p11;q24) (n=2) and 
t(8;22)(q24;q11) (n=3), detected by standard cytogenetics and/or fluorescence in situ 
hybridization (FISH). The four cases without evidence for MYC rearrangement 
presented karyotypes without mitosis and no material was available for FISH studies; 
however, a cytological, histological and immunophenotypic pattern characteristic of 
typical BL was observed in all of them. All patients received similar standard dose-
intense chemotherapy including cyclophosphamide, anthracyclines, etoposide, 
vincristine, dexamethasone/prednisone, methotrexate and cytarabine, without 
rituximab, plus intrathecal prophylaxis.22 Clinical and follow-up data was available for 
36 of the 39 BL patients. In addition, twenty cell lines derived from patients with BL 
were studied, including Seraphina, Namalwa, Jijoye, Daudi, Elijah, Nab2, Raji and 
EB1 (EBV+); KHM10B, Wien133, Balm9, DG75, Ramos, BL2, BL41, CA46, Blue1, 
P32 and Tanoue (EBV-); and BL5, a cell line derived from a patient with HIV-
associated BL (Supplementary-Table 2). The study was approved by the University of 
Navarra Institutional Review Board, and the clinical investigation was conducted 
according to Declaration of Helsinki principles. 
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Drugs 
Suberoylanilide hydroxamic acid (SAHA, Vorinostat) was kindly provided by Merck & 
Co. laboratories (Rahway, NJ, USA). In addition, 5-aza-2-deoxycitidine and etoposide 
(Sigma-Aldrich, Steinheim, Germany); doxorubicin and cytarabine (Pfizer Inc, New 
York, USA), vincristine (Stada, Bad Vilbel, Germany), methotrexate and 
dexamethasone (Merck), we used. 
 
Quantitative real-time polymerase chain reaction (QRT-PCR) and Western blot 
analyses 
Measurement of the expression of BIM (ABI-Hs.00197982), BAK (ABI-Hs.00832876) 
and BAX (ABI-Hs.00180269) genes was performed with QRT-PCR using the assay-
on-demand gene expression products in the ABI PRISM 7500 device (Applied 
Biosystems, Weitersadt, Germany). Expression levels were normalized with GAPDH 
(ABI-Hs.99999905) as an endogenous control. Expression of BCL2 family member 
proteins was studied by Western blotting in BL cell lines and primary biopsies. The 
following antibodies were used: Noxa (Oncogene Research Products, Boston, MA, 
USA); BIM, BAD, BID, BAK, BAX, MCL1 and BCL2 (Stressgen, Victoria, Canada), and 
Bcl-XL (Abcam, Cambridge, UK). To evaluate equal protein transfer, detection of Actin 
protein (Oncogene Research Products) was performed. To confirm homozygous 
deletion of BIM gene locus in two of the BL cell lines (P32 and BL2), PCR on genomic 
DNA was performed according to reported methods.14  
 
Methylation analysis of BIM promoter sequences 
 7
Detection of hypermethylation of human BIM gene promoter by standard methylation-
specific PCR (MSP) analysis was performed as previously reported.14 In addition, BIM 
methylation levels were measured using quantitative real-time methylation-specific 
PCR (QRT-MSP) in a rapid fluorescent thermal cycler with three-color fluorescence 
monitoring capability (LightCycler, Roche), using 1 μL of bisulfite-modified DNA in 10 
μl reaction volume with 0.4 μM each primer, and 1 μL of 10x LightCycler FastStar 
DNA Master SYBR Green I (Roche Molecular Biochemicals), as previously 
reported.23. For sequencing analysis of methylated areas, BIM promoter was amplified 
by nested-PCR after bisulfite modification. Amplification products obtained in the 
second PCR reaction were subcloned into pCR 4-TOPO plasmid using the TOPO TA 
Cloning Kit for Sequencing (Invitrogen Life Technologies, Paisley, UK) and 
transformed into Escherichia coli according to the manufacturer’s recommendations. 
Colonies with recombinant plasmids containing the described PCR products were 
screened by digestion with EcoRI (Amersham Biosciences, Buckinghamshire, UK). 
Candidate plasmid clones were sequenced in the ABI 3730 Genetic Analyzer 
sequencer (Applied Biosystems). To evaluate demethylation, BL cell lines grown at a 
density of 3x105 cells/mL in 25 cm2 flasks with 10 mL of culture medium were treated 
with 2 μM of the demethylating agent 5-aza-2-deoxycitidine or 2 μM of Vorinostat; 
after incubation of 96 hours, cells were harvested for MSP, QRT-PCR, and Western 
blot analyses.  
 
Quantitative Chromatin immunoprecipitation (ChIP) 
BL cells were treated with 2 μM of Vorinostat for 48 h and subjected to ChIP. 
Quantitative PCR (Q-PCR) analysis of the ChIP fractions (10 ng) from antibody-bound 
and input chromatin was performed to assess the acetylated Histone 3 (AcH3; Upstate 
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Biotechnologies, Lake Placid, NY, USA) modification in canonical CpG island 
sequences of the BIM promoter. SYBR Green detection was used in the LightCycler 
platform (Roche, Basel, Switzerland). The amplification of the ChIP fraction and of the 
input DNA were used as a target and reference sequences, respectively. They were 
amplified in the same run using BIM-ChipD (5´-AGACCTTCCCCAGACTTGCT-3´) and 
BIM-ChipR (5´-TCTTTGCCCAGGACAGACTT-3´) primers. The same program 
conditions that for QRT-MSP were applied to perform Q-PCR-Chip, and calculations 
were also performed automatically by the LightCycler software (see above). The level 
of AcH3 was determined relative to input chromatin of each sample. 
 
MYC and P53 gene sequencing analysis  
Direct sequencing of MYC gene at box I and of P53 (exons 4 to 8) was performed in 
the ABI 3730 sequencer, using the following primers: for MYC box I, forward, 5’-
ACCTCGACTACGACTCGGTG-3’; reverse,  5’-AGAAGCCGCTCCACATACAG-3’. For 
P53: forward 5’- CTGCCGTCTTCCAGTTGC-3’; reverse 5’-
TAAGCAGCAGGAGAAAGCCC-3’ for exons 4 and 5; forward 5’-
CGACAGAGCGAGATTCCATC-3’; reverse 5’- TCCCAAAGCCAGAGAAAAGA-3’ for 
exon 6; forward 5’-GGTTGGGAGTAGATGGAGCC-3’; reverse 5’-
CAAATGCCCCAATTGCAG-3’ for exons 7 and 8. 
 
Ectopic transfection of BIM by retroviral transduction 
Full-length BIM (BCL2L11) cDNA was cloned into the p-MIRG vector upstream from 
the internal ribosomal entry site (IRES) of the murine stem-cell virus (MSCV)–IRES–
enhanced green fluorescent protein (GFP). p-MIRG-BIM and p-MIRG (empty vector) 
were transfected into Propack-A.52 cells (CRL-12479 ATCC, Manassas, VA, USA) 
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using lipofectamine (Invitrogen). Then, retroviral supernatant was collected and filtered 
through 0.45 µm filter. Titer of the p-MIRG-BIM and p-MIRG vectors was determined 
by infecting 3T3 cells (DSMZ, Braunschweig, Germany) in the presence of 8 µg 
polybrene (Sigma-Aldrich). For transduction of the BL cells, a 24-well plate was coated 
with 2 µg/mL of retronectin (Takara, Shuzo, Otsu, Japan) at 4ºC, overnight. After 
removal of the retronectin solution, the plate was blocked for 30 min at room 
temperature with sterile PBS containing 2% BSA. To pre-load the retrovirus into the 
plate, blocking solution was removed and 500 µL of retroviral supernatant was added 
and incubated at room temperature for 1 h. After three additional pre-load steps, 1 
x105 cells were added to each well in RPMI/10% FBS containing 4 µg/mL polybrene 
(Sigma-Aldrich) and plates were then incubated at 37ºC under 5% CO2. GFP positive 
cells were finally isolated using a FACSAria cell sorter (Beckton Dickinson 
Biosciences, San Jose, California, USA). Measurement of BIM expression levels was 
performed using QRT-PCR and Western blot analyses. Finally, single-cell clones were 
isolated from the BIM-expressing cell pools, and two of them presenting moderate and 
high expression levels of BIM (Seraphina clones 1 and 2, respectively) were selected 
for this study.  
 
siRNA knockdown of BIM gene 
BIM silencing was performed in two cell lines expressing BIM (KHM10B and Ramos) 
by transfection of three siRNAs (s195011, s195012 and s19474) and the Silencer 
Negative Control-1 siRNA (Ambion, Austin, TX, USA) using the Cell Line Nucleofector 
Solution V in a nucleofector device (Amaxa GmbH, Köln, Germany). After siRNA 
transfection, BIM protein expression was evaluated by Western blotting at 48 hours.  
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Citotoxicity and apoptosis assays 
BL cells grown at a cell density of 1.2x106 cells/4 mL were treated with doxorubicin, 
vincristine, methotrexate, cytarabine, etoposide and dexamethasone at 1, 5, 10 and 
50 ng/mL,  alone or in combination with 2 μM of Vorinostat during 24 hours or with 2 
μM of 5-Aza during 72 hours. Cell viability was assessed by trypan-blue dye 
exclusion. To determine apoptosis, caspase 3 and 9 activation (with antibodies from 
BD Pharmingen and Stressgen, Victoria, BC, Canada, respectively) and PARP protein 
expression (with antibodies from Promega Corporation, Madison, WI, USA) were 
determined using Western blot. In addition, apoptosis was assessed by PS 
externalization using Annexin V/FITC in the presence of propidium iodide, and cell 
fluorescence was detected on a FACSCalibur using CellQuest Pro software, as 
reported.24 
 
Establishment of BL xenografts in immunodeficient mice and in vivo therapy 
All mouse experiments were performed in the Animal Core Facilities of CIMA 
(University of Navarra) after approval by the local Animal Ethics Committee. To 
evaluate whether BL cells with different BIM expression levels presented variable 
chemotherapy resistance in vivo, 2,5x106 Seraphina cells transfected with p-MIRG 
(empty vector) or with p-MIRG-BIM clones 1 and 2, and wild-type cells were 
intravenously (i.v.) injected into immunodeficient RAG2-/-IL2γc-/- mice, which lack B, T, 
and NK cells.25 Doxorubicin treatment was administered intraperitoneally (i.p.) on day 
14 (10 mg/Kg body weight) and day 21 (5 mg/Kg body weight) after inoculation, 
whereas control mice received the corresponding vehicle (PBS). To test whether re-
expression of BIM with Vorinostat therapy in BL cells was associated with modification 
of sensitivity to chemotherapy in vivo, 2,5×106 cells from wild-type Seraphina were i.v. 
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inoculated into RAG2-/-IL2γc-/- recipients. Vorinostat treatment commencing 14 days 
after BL-cell inoculation was administered i.p. for 14 days (75 mg/Kg body weight), 
with or without doxorubicin (administered i.p. on days 14 and 21 after inoculation, 10 
and 5 mg/Kg body weight, respectively). Control mice received the corresponding 
vehicle (DMSO). Mouse cohorts consisted of 5 to 8 mice each, and were clinically 
monitored and sacrificed when signs of tumor development were observed. To 
evaluate therapeutic efficacy at certain time points, mice were killed and enlarged 
lymph nodes and/or spleens were dissected, and apoptosis was evaluated as 
described above. 
 
Positron Emission Tomography (PET) imaging of tumors in mice 
To monitor tumor responses to chemotherapy in vivo, PET imaging was performed at 
certain time points in a dedicated small animal Philips Mosaic tomograph (Cleveland, 
Ohio, USA), with 2 mm resolution, 11.9 cm axial field of view (FOV) and 12.8 cm 
transaxial FOV. Mice were anesthetized with 2% isoflurane in 100% O2 gas for 18F-
FDG injection (10 MBq ± 2.38 in 80-100 µL) in a tail vein, and were immediately 
awakened afterwards and placed back in the cage. Fifty minutes after radiotracer 
administration, animals were placed prone on the PET scanner bed to perform a static 
acquisition (sinogram) of 15 minutes under continuous anesthesia. Images were 
reconstructed using the 3D Ramla algorithm (a true 3D reconstruction) with 2 
iterations and a relaxation parameter of 0.024 into a 128×128 matrix with a 1 mm 
voxel size applying dead time, decay, random and scattering corrections. For 
quantitative analysis of tumor 18 F-FDG uptake, regions of interest (ROIs) were drawn 
on coronal 1-mm-thick small-animal PET images. ROIs were drawn on several slices 
and finally, maximum standardized uptake value (SUVmax) was calculated for each 
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tumor using the formula SUV = tissue activity concentration/injected dose x body 
weight. SUVmax uptake expresses the glycolitic metabolism of tumor cells.  
 
Lymphoma characterization, B-cell isolation and therapy of Eμ-Myc and BIM-
deficient transgenes 
Eμ-Myc transgenic mice (C57BL/6J-Tg-IghMyc-22Bri/J) and BIM-/- knock-out mice 
(C57BL/6J-Bcl2l11tm1.1Ast/Bcl2l11tm1.1Ast) were purchased from The Jackson laboratory 
(Bar Harbor, Maine, USA).  Eμ-Myc mice were intercrossed with BIM-/- mice, and 
genotyping was performed to identify Eμ-Myc- BIM+/- and Eμ-Myc-BIM-/- mouse lines, 
as reported.20 Transgenic mice were clinically monitored and killed upon overt signs of 
disease were observed. Lymphoma cells were harvested and cell suspensions were 
analyzed by flow cytometry using B220 and IgM antibodies (both from Becton 
Dickinson) to distinguish mature B-cell lymphomas (B220+IgM+) from pre-B-cell 
lymphomas (B220+IgM-). To test response to chemotherapy in vitro, primary 
B220+IgM+ tumor lymphocytes were incubated in IMDM with 20%  inactivated FBS, 
55μM of β-mercaptoethanol and 10μg/mL of anti-IgM for BCR-activation. After 12 
hours, cells at a concentration of 2 610× cells/mL were treated for additional 12 hours 
with doxorubicin at a final concentration of 0.1μg/mL. Cell viability and apoptosis were 
evaluated as described above. To determine sensitivity of transgenic lymphomas to 
doxorubicin, 2.5x106 B220+IgM+ tumor lymphocytes obtained from Eμ-Myc or Eμ-
Myc-BIM+/- mice were intravenously injected into RAG2-/-IL2γc-/- mice. One week after 
inoculation, doxorubicin was administered i.p. (10 mg/Kg body weight), and tumor 
development was monitored and compared to control mice in the two transgenic 
subgroups.  
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Statistical analysis 
To determine the statistical differences between cell viabilities, p values were 
calculated by using one-way ANOVA test followed by Levene test to assess the 
homogeneity of variances (HOV). The different post hoc multiple comparison tests 
used were: Tukey in the case of HOV or Tamhane in the absence of HOV (for 
comparisons with control group), and Dunnett (for multiple comparisons). Kaplan-
Meier plots were depicted to evaluate overall survival (OS) of BL patients, xenografted 
mouse recipients and transgenic mice; 95% CI was computed using Kalbfleish-
Prentice method. Associations between individual clinical and biological features and 
OS were determined using the log-rank (Mantle-Cox) test.  The analyses were carried 
out using the SPSS 15.0 statistical software (SPSS Inc., Chicago, IL, USA) for 
Windows. For comparison between median values, Fischer exact test was used. 
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RESULTS 
 
Epigenetic silencing of pro-apoptotic BIM correlates with chemoresistance in 
patients with Burkitt lymphoma/leukemia 
Our previous integrative genomic and gene expression profiling study identified 
frequent homozygous deletion of BIM gene in mantle cell lymphoma. In addition, BIM 
promoter hypermethylation was detected in germinal center-derived B-cell 
lymphomas, including follicular lymphoma, diffuse large B-cell lymphoma and BL.14 To 
expand this initial observation, we applied standard and quantitative methylation-
specific PCR (MSP) and sequencing analyses of CpG islands of BIM gene promoter 
to BL samples, detecting BIM hypermethylation in 17 of 39 (46%) patient biopsies and 
in 15 of 18 (83%) cell lines (Figure 1A). Two additional BL cell lines, P32 and BL2, 
exhibited BIM gene inactivation by bi-allelic deletion (Figure 1B). Quantitative PCR 
analysis of chromatin immunoprecipitation (ChIP) fractions showed decrease of 
acetylated Histone 3 (AcH3) in canonical CpG island sequences of BIM promoter in 
hypermethylated cell lines but not in non-methylated tumors (Figure 1C). Concurrent 
BIM methylation and deacetylation were correlated with very low or absent RNA and 
protein expression levels (Figure 1D). Accordingly, treatment of methylated cells with 
the demethylating agent 5-Aza-2-deoxycitidine (5-Aza) or with the HDACi Vorinostat 
resulted in 1.5 to 4-fold BIM re-expression, while Vorinostat significantly increased 
AcH3 levels (Figures 1C and 1E). These data indicate that epigenetic silencing of BIM 
gene by both hypermethylation and deacetylation occurs frequently in BL and can be 
pharmacologically reversed. To investigate whether BIM hypermethylation was 
correlated with clinical features, we analyzed a series of 36 Spanish patients with BL 
who received similar intensive chemotherapeutic regimens plus central nervous 
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system prophylaxis.22 Patient’s clinical and laboratory data are shown in Table 1 and 
Supplementary-Table 1. All but four were adults and the median age was 39 years 
(range, 4-76). The majority (82%) presented extranodal involvement including bone 
marrow and leukemic disease (75%). Twenty-one of 36 patients (58%) achieved CR, 
resulting in a median OS of 15 months (95% confidence interval (CI): 0.4;29.5) (Figure 
2A). BIM promoter hypermethylation was detected in 17 of 36 (47%) patient samples 
whereas 19 cases presented non-methylated BIM gene. At diagnosis, patients with 
methylated and unmethylated BIM were not distinguishable by the clinical and 
laboratory features typically associated with poor prognosis in BL (Table 1 and 
Supplementary-Figure 1A). However, patients with methylated BIM presented lower 
CR rate, as only 4 of 17 cases achieved CR vs. 15 of 19 patients in the unmethylated 
subgroup (24% vs. 79%; p=0.002). Accordingly, BIM hypermethylation was associated 
with shorter OS (median OS, 2 months vs. not reached; p=0.007) (Figure 2B and 
Supplementary-Figure 1B). Similar survival data were observed for patients under 50 
years of age (Supplementary-Figure 1C). These data indicate that BIM transcriptional 
repression is correlated with chemotherapeutic resistance, leading to lower CR and 
shorter survival duration of patients with BL.  
 
Biological features of BL cases with BIM hypermethylation 
We explored whether BIM transcriptional silencing was correlated with EBV-infection 
status in BL cells. By quantitative MSP, higher hypermethylation levels of BIM gene 
were detected in EBV+ lymphomas compared to EBV- tumors (mean value, 91±13 vs. 
35±22; p<0.01) (Figure 2C. In previous reports, box I MYC mutations targeting Pro-57 
and Thr-58 enhanced MYC transformation and promoted B-cell lymphoma 
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development in mice by evading apoptosis as a result of a failure to induce BIM.21,26 
Direct sequencing revealed that box I MYC mutations spanning aminoacid positions 
57 to 60 were more frequent in BL cells BIM hypermethylation than in non-methylated 
tumors (p=0.19) (Figure 2D and Supplementary-Figure 2A). Although statistical 
significance was not reached, these data suggest that MYC mutations may have 
played a role in the epigenetic silencing of BIM. Next, the expression of the BCL2-
family member proteins, which are critical regulators of apoptosis in B-cell 
malignancies, was measured by Western blotting in BL samples. Tumors with 
unmethylated BIM presented a higher number of alterations in the BCL2-family 
proteins in comparison with the hypermethylated cell lines (Figure 2E). BAK and BAX 
proteins, two final effectors of the apoptotic cascades, presented null or very low 
expression in the unmethylated cell lines while showing normal expression at the RNA 
level, pointing out to a post-transcriptional mechanism as the putative cause of 
BAK/BAX down-regulation (Supplementary-Figure 2B). Additional studies revealed 
that only 2 of 9 primary hypermethylated BL biopsies showed P53 mutations whereas 
these were detected in 6 of 15 non-methylated BL samples (22% vs. 40%; p=0.24) 
(Figure 2F). Together, these results indicate that transcriptional repression of BIM in 
BL cells may be sufficient to evade apoptosis, requiring a reduced number of lesions 
in other apoptotic regulatory proteins or in P53.20,21 Therefore, BIM seems to function 
as a critical regulator of apoptosis in BL cells. 
 
BL resistance to doxorubicin correlates with BIM expression levels 
Patients with BL are currently treated with dose-intensive chemotherapy regimens 
including cyclophosphamide, doxorubicin, vincristine, methotrexate, etoposide, 
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dexamethasone and cytarabine.3,4 To test whether BIM expression was correlated 
with differences in cytotoxicity profiles, Seraphina cell line, which exhibits complete 
BIM epigenetic silencing, was retrovirally transfected with a p-MIRG-BIM expressing 
vector (Figure 3A). Two Seraphina single-cell clones with elevated BIM expression 
(clone 1 with a 2-fold increase, and clone 2 with a 2.5-fold increase with respect to 
parental cells) were incubated with the chemotherapeutic agents. A statistically 
significant decrease in cell viability was observed with doxorubicin (which increased 
cytotoxicity rates 20-30% in comparison to control cells). However, these differences 
were not displayed with etoposide, methotrexate, cytarabine, dexamethasone and 
vincristine treatment (Figure 3A and Supplementary Figure 3). We could not test 
cyclophosphamide, as this drug is inactive until undergoes hepatic metabolism.27 
Treatment with doxorubicin induced cell death through the mitochondrial apoptotic 
pathway, as shown by activation of caspase 9 and increase of PARP (Figure 3B). 
Next, BIM was silenced using siRNA in BIM-expressing BL cell lines Ramos and 
KHM10B, which were incubated with the chemotherapeutic drugs. After doxorubicin 
treatment, cell viability was increased along with a decrease in apoptotic rates 
(roughly, 30-40%) in BIM-silenced cells in comparison to control cells (Figure 3C). 
These data indicate that selective resistance of BL cells to doxorubicin is partially 
conditioned by BIM expression levels. To test whether similar results could be 
observed in vivo, Seraphina clones 1 and 2 were i.v. inoculated into RAG2-/-IL2γc-/- 
mice, which received doxorubicin or vehicle treatments. Mice carrying wild-type cells 
or cells transfected with the empty vector did not show differences in OS between 
treated and vehicle-treated subgroups. Conversely, mice injected with clones 1 and 2 
receiving doxorubicin presented longer OS in comparison to vehicle-treated recipients, 
being these differences were more pronounced for mice carrying clone 2-derived 
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lymphomas (median OS, 32 vs. 22 days; p<0.001) than for those with clone 1 (29 vs. 
25 days, p=0.01) (Figure 3D). Accordingly, reduction of lymphoma volumes and 
decreased glycolitic tumor activities were observed in recipients transplanted with 
clones 1 and 2 cells in comparison to control mice, as determined by PET imaging 
studies (Figure 3E). These data indicate that sensitivity to doxorubicin is correlated 
with BIM expression in BL xenografts in vivo, therefore expanding our previous 
observations in vitro. 
 
BIM regulates chemoresistance in lymphomas developed in Eμ-MYC and BIM-
deficient mice 
A previous study demonstrated that BIM-mutant Eμ-MYC transgenic mice developed 
B-cell leukemias and lymphomas more efficiently than Eμ-MYC transgenes (Figure 4A 
and Supplementary-Figure 4).20 We used this validated model to test whether BIM 
could condition sensitivity to chemotherapy in mouse B-cell lymphomas. First, mature 
B220+IgM+ tumor lymphocytes were isolated from Eμ-MYC or in Eμ-MYC-BIM+/- 
transgenes and treated with doxorubicin ex vivo. Eμ-MYC lymphoma cells showed 
decreased survival and higher apoptotic levels than Eμ-MYC-BIM+/- lymphoma cells 
after doxorubicin treatment (Figure 4B). To test this observation in vivo, 2.5x106 
mature B220+IgM+ tumor lymphocytes isolated from six different lymphomas 
developed in Eμ-MYC or in Eμ-MYC-BIM+/- transgenes were injected i.v. into RAG2-/-
IL2γc-/- recipients (Supplementary-Table 3). One week after inoculation, doxorubicin 
vs. vehicle-DMSO was administered (Figure 4C). After treatment and in comparison to 
DMSO-treated mice, mice carrying Eμ-MYC lymphomas presented an extended 
survival time of 30 days (median OS, 20 vs. 50 days; p=0.001) whereas those with 
Eμ-MYC-BIM+/- lymphomas only extended survival in 8 days (median OS, 40 vs. 48 
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days; p=0.03) (Figure 4D). Thus, mice Eμ-MYC-BIM+/- lymphomas were more 
resistant to chemotherapy than the Eμ-MYC subgroup in vivo. Moreover, at day 100 
post-injection, four Eμ-MYC mouse recipients remain disease-free vs. only two in the 
Eμ-MYC-BIM+/- subgroup. Accordingly, PET studies showed a marked reduction in the 
glycolitic tumor activity in Eμ-MYC lymphoma-recipients in comparison to mice with 
Eμ-MYC-BIM+/- lymphomas after doxorubicin treatment (Figure 4E). These data 
confirm our previous results in a different mouse model, reinforcing the concept that 
BIM expression levels modulate chemosensitivity in MYC-driven lymphomas.  
 
BL chemoresistance can be overcome by pharmacological re-expression of BIM 
Last, to begin to translate these findings to the clinic, we tested whether resistance to 
chemotherapy was reversible upon pharmacological induction of BIM expression in 
BL-resistant lymphomas. Treatment of BIM epigenetically-silenced cell lines with 5-
Aza induced a 1.5 to 2.5-fold up-regulation of BIM expression, while treatment with 
Vorinostat resulted in a 3.5 to 4-fold BIM re-expression (Figure 1E). Induction of BIM 
in BL cells was associated with a partial reversion of the resistance to doxorubicin in 
vitro along with an increase in the apoptotic rates, which were more pronounced for 
Vorinostat than for 5-Aza (Figure 5A). We therefore selected Vorinostat to explore 
whether similar results could be observed in vivo. Thus, 2.5×106 cells from wild-type 
Seraphina cell line (with complete BIM hypermethylation) were i.v. inoculated into four 
RAG2-/-IL2γc-/- mouse cohorts that received Vorinostat, doxorubicin, Vorinostat plus 
doxorubicin, or vehicle (DMSO). Vorinostat was administered at low doses, enough to 
induce BIM expression without killing the lymphoma cells in vitro (data not shown). 
Accordingly, mice treated with DMSO presented similar survival duration than the 
Vorinostat-treated subgroup (median OS, 27 days). In contrast, doxorubicin-treated 
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mice presented longer survival (median OS, 33 vs. 27 days, p<0.01), but the 
Vorinostat and doxorubicin group had the longest OS (median OS, 37 vs. 27 days; 
p<0.001) (Figure 5B). Treatment of tumors with Vorinostat plus doxorubicin was 
associated with activation of the intrinsic apoptotic pathway (Figures 5C and 5D). 
Additionally, monitorization of tumor responses using PET imaging showed a marked 
reduction in tumor volume and glycolitic activity in mice treated with Vorinostat and 
doxorubicin in comparison to the other mouse cohorts (Figure 5E). These data 
indicate that the combination of Vorinostat at low doses (which allows re-expression of 
BIM thus sensitizing cells to chemotherapy) followed by doxorubicin was the optimal 
therapeutic in the xenograft model.  
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DISCUSSION 
Our study demonstrates the power of coupling clinical investigation with experimental 
research to deal with a medical problem. We have used different in vitro assays and 
studies in human BL xenografts and transgenic mice to show that the epigenetic 
silencing of BIM is a critical mechanism of chemotherapy resistance in MYC-driven 
lymphomas. Accordingly, therapies that reactivate BIM function such as Vorinostat 
can reverse chemoresistance and enhance the efficacy of doxorubicin therapy in BL. 
Other studies aiming to evaluate the apoptosis and therapeutic activities of HDACis 
have been conducted in similar mouse models of lymphoma.28,29 These and our report 
underline the importance of using appropriate experimental animal models for the pre-
clinical evaluation of novel therapeutic agents, aiming to select optimal drug 
combinations to treat human disease.  
This report includes a series of patients with aggressive Burkitt lymphoma/leukemia, 
as most of them were adults showing an extramedullary disease, mainly bone marrow 
involvement and leukemic dissemination.3,4 Although our series may include more 
aggressive cases than other reported series of BL, the fact that almost half of our 
patients were refractory to initial chemotherapy allowed us to observe the correlation 
between the failure to achieve CR and the presence of BIM hypermethylation. We 
however believe that the percentage of such resistant cases with epigenetic silencing 
of BIM may be lower in other series of pediatric and adult BL patients.  
BIM plays a central role in the therapeutic resistance of some solid tumors and 
myeloid leukemias, whereby BIM inactivation is caused by selective phosphorilation 
that targets it for degradation in the proteasome. This post-transcriptional BIM 
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inactivation mediated therapeutic resistance to tyrosine-kinase inhibitors in lung 
cancer,30 MEK inhibitors in melanomas,31 paclitaxel in epithelial tumors,15 imatimib in 
chronic myeloid leukemia,16 and sorafenib (a RAF kinase inhibitor) in acute myeloid 
leukemia.32 Restoration of BIM expression with the proteasome inhibitor bortezomib or 
by mimicking its function with the BH3-mimetic ABT-737 reversed tumor 
chemoresistance.15,16,30-32 Herein, we confirm the critical role of BIM in regulating 
chemoresistance but, differently to these reports, BIM inactivation occurred at the 
transcriptional level and not post-transcriptionally. This conclusion is of clinical 
relevance, because the reactivation of BIM function aiming to by-pass 
chemoresistance in BL should be performed with therapies such as demethylating 
agents or HDACis that can reverse the epigenetic silencing of BIM, and not with 
bortezomib of ABT-737 that could be used to treat solid tumors with BIM inactivation.  
The data presented has prompted us to try to test the combination of Vorinostat with 
dose-intensive chemotherapy in patients with BL. Consequently, a phase I/II clinical 
trial has been recently approved by the Spanish cooperative group PETHEMA, with 
the end-point of determining the maximum tolerated dose and the therapeutic efficacy 
of Vorinostat in combination with rituximab and HyperCVAD in adult patients with 
refractory or early relapsed BL. Vorinostat as a single agent has been approved by the 
FDA in October 2006 for the treatment of progressive, persistent or recurrent 
cutaneous T-cell lymphoma after two prior systemic therapies, achieving clinical 
effective responses with an acceptable safety profile.33 However, there is not 
extensive experience with Vorinostat in combination with chemo-immunotherapy in 
patients with mature B-cell lymphomas.34 The results of several ongoing clinical trials 
(such as the NCT00667615 and NCT00601718; www.clinicaltrials.gob) and our own 
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experience will provide valuable information about the clinical effectiveness and 
toxicity profile of this drug combination in the treatment of patients with BL.  
 24
 
ACKNOWLEDGMENTS 
  
We thank Drs. Martin Dyer (University of Leicester, Leicester, UK), William Harrington 
(University of Miami, Miami, USA) and James Stone (University of Alberta, Edmonton, 
Canada) for providing cell lines, Drs. Maria Collantes and Iván Peñuelas (University of 
Navarra) for mouse imaging studies, Dr. Marta García-Granero (University of Navarra) 
for support with the statistical studies, and Izaskun Sesma for excellent technical work 
with mice. This work was supported by the Spanish Ministry of Science and Innovation 
(grants PI081878 and RTICC-RD06/0020-0088/0111/0066/0006), the Navarra 
Government (Education and Health Councils), the CITTIL Spanish-French EU 
Program, and the UTE-CIMA project. J.A.R.-L. and E.B. are supported by pre-doctoral 
fellowships from the Spanish Ministry of Science and Innovation.  
 
DISCLOSURES 
 
No relevant conflicts of interest to declare. 
 
AUTHORSHIPS 
Jose A. Richter-Larrea: designed the study, performed most of the research of the 
manuscript, analyzed and interpreted the data 
Eloy F. Robles: performed research, analyzed and interpreted data 
Vicente Fresquet: performed research, analyzed and interpreted data 
Elena Beltran: performed research, analyzed and interpreted data 
Antonio J. Rullan: performed research, analyzed and interpreted data 
M.ª José Calasanz: contributed samples, performed research 
Carlos Panizo: contributed samples, performed research  
Jose A. Richter: performed research, analyzed and interpreted data  
 25
Xabier Agirre: performed research, analyzed and interpreted data 
Jesus M. Hernandez: contributed samples, performed research 
Jose Roman-Gomez: contributed samples, performed research, analyzed and 
interpreted data 
Felipe Prosper: contributed samples, analyzed and interpreted data 
Jose A. Martinez-Climent: design the study, analyzed and interpreted data, wrote the 
manuscript 
 
 
 
 
 
 
 
 
 
 26
REFERENCES 
 
1. Jaffe ES, Harris NL, Stein H, Isaacson PG. Classification of lymphoid 
neoplasms: the microscope as a tool for disease discovery. Blood. 2008;112:4384-4399. 
2. Gelmann EP, Psallidopoulos MC, Papas TS, Dalla-Favera R. Identification of 
reciprocal translocation sites within the c-myc oncogene and immunoglobulin mu locus 
in a Burkitt lymphoma. Nature. 1983;306:799-803. 
3. Blum KA, Lozanski G, Byrd JC. Adult Burkitt leukemia and lymphoma. Blood. 
2004;104:3009-3020. 
4. Yustein JT, Dang CV. Biology and treatment of Burkitt's lymphoma. Curr Opin 
Hematol. 2007;14:375-381. 
5. Garcia JL, Hernandez JM, Gutierrez NC, et al. Abnormalities on 1q and 7q are 
associated with poor outcome in sporadic Burkitt's lymphoma. A cytogenetic and 
comparative genomic hybridization study. Leukemia. 2003;17:2016-2024. 
6. Murphy SB, Fairclough DL, Hutchison RE, Berard CW. Non-Hodgkin's 
lymphomas of childhood: an analysis of the histology, staging, and response to 
treatment of 338 cases at a single institution. J Clin Oncol. 1989;7:186-193. 
7. Levine AM. Challenges in the management of Burkitt's lymphoma. Clin 
Lymphoma. 2002;3 Suppl 1:S19-25. 
8. Bociek RG. Adult Burkitt's lymphoma. Clin Lymphoma. 2005;6:11-20. 
9. Griffin TC, Weitzman S, Weinstein H, et al. A study of rituximab and 
ifosfamide, carboplatin, and etoposide chemotherapy in children with 
recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute 
lymphoblastic leukemia: a report from the Children's Oncology Group. Pediatr Blood 
Cancer. 2009;52:177-181. 
10. Gutierrez MI, Cherney B, Hussain A, et al. Bax is frequently compromised in 
Burkitt's lymphomas with irreversible resistance to Fas-induced apoptosis. Cancer Res. 
1999;59:696-703. 
11. Valnet-Rabier MB, Challier B, Thiebault S, et al. c-Flip protein expression in 
Burkitt's lymphomas is associated with a poor clinical outcome. Br J Haematol. 
2005;128:767-773. 
12. Tafuku S, Matsuda T, Kawakami H, Tomita M, Yagita H, Mori N. Potential 
mechanism of resistance to TRAIL-induced apoptosis in Burkitt's lymphoma. Eur J 
Haematol. 2006;76:64-74. 
13. Nomura Y, Yoshida S, Karube K, et al. Estimation of the relationship between 
caspase-3 expression and clinical outcome of Burkitt's and Burkitt-like lymphoma. 
Cancer Sci. 2008;99:1564-1569. 
14. Mestre-Escorihuela C, Rubio-Moscardo F, Richter JA, et al. Homozygous 
deletions localize novel tumor suppressor genes in B-cell lymphomas. Blood. 
2007;109:271-280. 
15. Tan TT, Degenhardt K, Nelson DA, et al. Key roles of BIM-driven apoptosis in 
epithelial tumors and rational chemotherapy. Cancer Cell. 2005;7:227-238. 
16. Kuroda J, Puthalakath H, Cragg MS, et al. Bim and Bad mediate imatinib-
induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome 
by a BH3 mimetic. Proc Natl Acad Sci U S A. 2006;103:14907-14912. 
17. Bouillet P, Metcalf D, Huang DC, et al. Proapoptotic Bcl-2 relative Bim 
required for certain apoptotic responses, leukocyte homeostasis, and to preclude 
autoimmunity. Science. 1999;286:1735-1738. 
 27
18. Bouillet P, Purton JF, Godfrey DI, et al. BH3-only Bcl-2 family member Bim is 
required for apoptosis of autoreactive thymocytes. Nature. 2002;415:922-926. 
19. Enders A, Bouillet P, Puthalakath H, Xu Y, Tarlinton DM, Strasser A. Loss of 
the pro-apoptotic BH3-only Bcl-2 family member Bim inhibits BCR stimulation-
induced apoptosis and deletion of autoreactive B cells. J Exp Med. 2003;198:1119-
1126. 
20. Egle A, Harris AW, Bouillet P, Cory S. Bim is a suppressor of Myc-induced 
mouse B cell leukemia. Proc Natl Acad Sci U S A. 2004;101:6164-6169. 
21. Hemann MT, Bric A, Teruya-Feldstein J, et al. Evasion of the p53 tumour 
surveillance network by tumour-derived MYC mutants. Nature. 2005;436:807-811. 
22. Oriol A, Ribera JM, Bergua J, et al. High-dose chemotherapy and 
immunotherapy in adult Burkitt lymphoma: comparison of results in human 
immunodeficiency virus-infected and noninfected patients. Cancer. 2008;113:117-125. 
23. Roman-Gomez J, Cordeu L, Agirre X, et al. Epigenetic regulation of Wnt-
signaling pathway in acute lymphoblastic leukemia. Blood. 2007;109:3462-3469. 
24. Rubio-Moscardo F, Blesa D, Mestre C, et al. Characterization of 8p21.3 
chromosomal deletions in B-cell lymphoma: TRAIL-R1 and TRAIL-R2 as candidate 
dosage-dependent tumor suppressor genes. Blood. 2005;106:3214-3222. 
25. Traggiai E, Chicha L, Mazzucchelli L, et al. Development of a human adaptive 
immune system in cord blood cell-transplanted mice. Science. 2004;304:104-107. 
26. Bhatia K, Huppi K, Spangler G, Siwarski D, Iyer R, Magrath I. Point mutations 
in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse 
plasmacytomas. Nat Genet. 1993;5:56-61. 
27. de Jonge ME, Huitema AD, Rodenhuis S, Beijnen JH. Clinical pharmacokinetics 
of cyclophosphamide. Clin Pharmacokinet. 2005;44:1135-1164. 
28. Lindemann RK, Newbold A, Whitecross KF, et al. Analysis of the apoptotic and 
therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell 
lymphoma. Proc Natl Acad Sci U S A. 2007;104:8071-8076. 
29. Frew AJ, Lindemann RK, Martin BP, et al. Combination therapy of established 
cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist. Proc Natl 
Acad Sci U S A. 2008;105:11317-11322. 
30. Cragg MS, Kuroda J, Puthalakath H, Huang DC, Strasser A. Gefitinib-induced 
killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be 
enhanced by BH3 mimetics. PLoS Med. 2007;4:1681-1689; discussion 1690. 
31. Cragg MS, Jansen ES, Cook M, Harris C, Strasser A, Scott CL. Treatment of B-
RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by 
a BH3 mimetic. J Clin Invest. 2008;118:3651-3659. 
32. Zhang W, Konopleva M, Ruvolo VR, et al. Sorafenib induces apoptosis of AML 
cells via Bim-mediated activation of the intrinsic apoptotic pathway. Leukemia. 
2008;22:808-818. 
33. Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in 
patients with persistent, progressive, or treatment refractory cutaneous T-cell 
lymphoma. J Clin Oncol. 2007;25:3109-3115. 
34. Crump M, Coiffier B, Jacobsen ED, et al. Phase II trial of oral vorinostat 
(suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Ann 
Oncol. 2008;19:964-969. 
 
 
 
 28
 
TABLE 1 
 
Table 1                         Clinical and Laboratory Characteristics of 36 Patients with BL 
     
 
Whole 
series BIM methylated BIM unmethylated  
Number of patients 36 17 (47%) 19 (53%) p value  
Age (Years)     
Median 39 43 36  
Range (4-76) (6-76) (4-68)  
<14 years 4 (11%) 1 (6%) 3 (16%) 0.6 
 
    
Sex     
Male 24 (67%) 12 (71%) 12 (63%)  
Female 12 (33%) 5 (29%) 7 (37%) 0.73 
Diagnosis     
Burkitt lymphoma 9 (25%) 5 (29%) 4 (21%) 0.71 
Burkitt lymphoma-leukemia 27 (75%) 13 (76%) 14 (74%)  
Stage III/IV 34 (94%) 17 (100%) 17 (89%) 0.48 
Bulky disease 1  11 (32%) 4 (27%) 7 (37%) 0.71 
Extranodal involvement 1  28 (82%) 12 (80%) 16 (84%) 1 
LDH level > 1000 IU 2  21 (66%) 9 (69%) 12 (63%) 1 
Complete remission  19 (53%) 4 (24%) 15 (79%) 0.002 
(1) Data available  on 34 
patients)     
(2) Data available  on 32 
patients     
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FIGURE LEGENDS 
 
Figure 1. Epigenetic silencing of pro-apoptotic BIM gene in Burkitt lymphoma. 
(A) Standard MSP analysis of the BIM gene in BL-derived cell lines and patient 
samples (P1 and P2, unmethylated BIM; P3 and P4, methylated BIM) (top left). 
Quantitative analysis of methylation using quantitative MSP (bottom left), including cell 
lines with complete methylation according to standard MSP analysis (light grey), cell 
lines with partial methylation (dark grey), and unmethylated tumors (DG75, Tanoue 
and BALM9). PB: peripheral blood. Right: Sequencing analysis of the BIM promoter 
region after bisulfite modification. Black boxes indicate methylated cytosines while 
white boxes correspond to unmethylated cytosines in CpG  dinucleotides. PB cells 
and BALM9 cell line (unmethylated), and the Seraphina cell line and a BL lymph-node 
biopsy from patient P4 (methylated), are shown. (B) Homozygous deletion of BIM 
gene in the EBV- P32 and BL2 cell lines, as revealed by a-CGH and PCR on tumor 
genomic DNA, resulting in null expression of BIM as shown by quantitative RT-PCR 
and Western blot analyses. (C) Quantitative ChIP assay of AcH3 binding to canonical 
CpG island sequences of BIM promoter in Vorinostat-treated and untreated cells. An 
increase of AcH3 levels after treatment with Vorinostat was detected in the 
hypermethylated Jijoye and Seraphina cell lines, but not in the unmethylated BALM9 
cell line. (D) BIM epigenetic silencing was correlated with absent or low expression at 
RNA levels measured by QRT-PCR (top) and protein levels as determined by Western 
blot analysis (bottom) in BL derived cell lines and patient samples (P1 and P2, 
unmethylated BIM; P3, P4 and P5, methylated BIM). (E) Treatment with 5-Aza and 
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with Vorinostat restored BIM expression in methylated tumors at the RNA and protein 
levels.  
 
Figure 2. Correlation of BIM epigenetic silencing with clinical outcome and with 
biological features in Burkitt lymphoma/leukemia. Kaplan-Meier curves for overall 
survival (OS) for (A) thirty-six patients with BL included in the study, and (B) for BL 
patients with methylated and unmethylated BIM, where BIM promoter 
hypermethylation was correlated with inferior CR rate (p=0.002) and shorter survival 
duration (p=0.007). (C) By MSP analysis, BIM hypermethylation was observed in eight 
EBV+ BL cell lines and in six of nine (66%) EBV- BL cell lines. By quantitative MSP 
analysis, measurement of BIM promoter hypermethylation according to EBV infection 
revealed higher hypermethylation levels in EBV+ lymphomas compared to EBV- 
tumors (p<0.01). (D) Correlation of box I MYC mutations in BL primary samples and 
cell lines with and without hypermethylation of BIM: mutations at box I from aminoacid 
position 57 to 60 (including Pro-57 and Thr-58 sites) were more frequent in BL cell 
lines and primary samples with BIM hypermethylation than in non-methylated tumors 
(12 of 24 cases, 50% vs. 6 of 16 cases, 37.5%; p=0.19). (E) Western blot analysis of 
BCL2 family proteins in BL cell lines, classified in methylated and unmethylated BIM 
subgroups. β-actin served as loading control. (F) Sequencing of P53 gene identified a 
lower number of mutations in patient samples with hypermethylated BIM with respect 
to unmethylated samples. Because almost all BL cell lines carried P53 mutations, this 
analysis was restricted to primary tumors.  
 
Figure 3. Correlation of BIM expression levels with chemotherapy-induced 
apoptosis. (A) Seraphina cells were retrovirally transfected with p-MIRG-BIM and p-
MIRG (empty vector). Single-cell clones were isolated from the BIM-expressing cell 
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pools. Using QRT-PCR and Western blot analyses, clones 1 and 2 showed 
intermediate and high BIM expression, respectively, with respect to the parental cell 
line.  Seraphina clones 1 and 2 were incubated with individual chemotherapeutic 
agents, showing increased sensitivity to doxorubicin with respect to control cells, but 
not to other compounds tested (Supplementary Figure 3). (B) Chemotherapy 
treatment of clones 1 and 2 cells activated the intrinsic apoptotic pathway, through 
cleavage of caspase 9 and expression of PARP proteins, as determined by Western 
blot analysis. (C) Silencing of BIM by RNA interference in Ramos and KHM10B cell 
lines was correlated with an increase in the resistance profile to doxorubicin with 
respect to parental cell line and control (cells transfected with a scramble vector). (D) 
Kaplan-Meier survival curves of RAG2-/-IL2γc-/- mice transplanted with wild-type and 
genetically manipulated Seraphina cells, which received chemotherapy or vehicle after 
tumor inoculation. Mice injected with Seraphina-transfected clones 1 and 2 cells but 
not Seraphina wild-type or cells transfected with the empty vector presented a 
statistically significant prolonged OS after treatment with doxorubicin in comparison to 
vehicle-treated recipients. (E) Follow-up studies of tumor metabolic activity by micro 
PET performed two weeks after initiation of therapy revealed a better response after 
treatment in Seraphina clone 1 recipients than in clone 2 transplanted mice, whereas 
no response was observed in control mice carrying BL cells transfected with empty p-
MIRG or parental wild-type cells. SUVmax, maximum standardized uptake value. 
 
Figure 4. Lymphoma characterization, B-cell isolation and therapy of double Eμ-
Myc and BIM-deficient transgenic mice. (A) Kaplan-Meier survival curves for Eμ-
MYC and Eμ-Myc-BIM+/- mice. (B) Mature B220+IgM+ tumor lymphocytes isolated 
from Eμ-MYC and Eμ-Myc-BIM+/- mice were BCR-activated with anti-IgM and treated 
with doxorubicin. Eμ-Myc B220+IgM+ lymphoma cells showed decreased survival and 
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higher apoptotic levels than Eμ-Myc-BIM+/- B220+IgM+ lymphoma cells, according to 
annexin V/FITC staining. (C) Representative diagram of the experimental therapeutic 
design to test whether Eμ-MYC lymphoma cells were more sensitive than Eμ-MYC-
BIM+/- lymphoma cells to doxorubicin treatment in vivo. (D) Kaplan-Meier survival 
curves for mice transplanted with mature B-cell Eμ-Myc and Eμ-Myc-BIM+/- lymphoma 
cells treated with doxorubicin vs. vehicle. In comparison to DMSO-treated mouse 
recipients, mice carrying Eμ-Myc lymphomas presented longer survival after therapy 
than those with Eμ-Myc-BIM+/- lymphomas. E) Micro-PET studies showed a significant 
reduction in the glycolitic tumor activity in Eμ-Myc lymphoma-recipients in comparison 
to mice with Eμ-Myc-BIM+/- lymphomas. PET studies were performed at day 7 (just 
before initiation of therapy) and at day 14 (one week after therapy). 
  
Figure 5. Resistance to doxorubicin is reversible upon treatment with HDACis in 
human BL-xenografted mice. (A) Treatment of BL cells with 5-Aza or Vorinostat 
resulted in BIM re-expression (Figure 1E). Subsequent incubation of these cells with 
doxorubicin led to a higher decrease in cell viability in Seraphina and Jijoye cells 
treated with Vorinostat vs. 5-Aza therapy. (B) Experimental design and Kaplan-Meier 
survival curves for four mouse cohorts transplanted with Seraphina cells with BIM 
hypermethylation and treated with vehicle (DMSO), low-dose Vorinostat, doxorubicin, 
and low-dose Vorinostat plus doxorubicin. Those receiving the combination of 
Vorinostat and doxorubicin presented longer OS with respect to the other subgroups. 
(C) An increase in the apoptotic rates was observed upon treatment with Vorinostat 
and doxorubicin in Seraphina and Jijoye cells in comparison to other in vitro 
treatments, as determined by annexin V/PI staining. (D) Representative study of the 
induction of apoptosis in Seraphina cells after treatment with Vorinostat plus 
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doxorubicin, as shown by caspase 3 and 9 activation and increased PARP 
expression. (E) Micro PET studies showed that mice treated with Vorinostat plus 
doxorubicin presented a significant decreased in tumor activity in comparison to mice 
treated with Vorinostat or doxorubicin, which was correlated with prolonged survival. 
Images were taken two weeks after treatment with the corresponding compound.  
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